Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Vande Broek

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Plos One|November 14, 2013
Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patientsSong Xu, Gaia Cecilia Santini, Kim De Veirman, et al.
Cancers|October 14, 2022
Liquid Biopsy-Derived DNA Sources as Tools for Comprehensive Mutation Profiling in Multiple Myeloma: A Comparative StudyRobbe Heestermans, Wouter De Brouwer, Ken Maes, et al.
Cancer Research|June 18, 2009
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myelomaSarah Deleu, Miguel Lemaire, Janine Arts, et al.
Anticancer Research|December 6, 2015
Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced MelanomaLore Decoster, Isabelle Vande Broek, Bart Neyns, et al.
Acta Pharmacologica Sinica|April 9, 2013
Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivoSong Xu, Kim De Veirman, Holly Evans, et al.
Blood|June 10, 2010
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrugJinsong Hu, Damian R Handisides, Els Van Valckenborgh, et al.
Acta Clinica Belgica|September 26, 2019
Real-world data confirming the efficacy and safety of decitabine in acute myeloid leukaemia - results from a retrospective Belgian registry studyStef Meers, Benjamin Bailly, Isabelle Vande Broek, et al.
Haematologica|April 22, 2006
The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM modelEline Menu, Kewal Asosingh, Stefano Indraccolo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survivalElke De Bruyne, Tomas Jan Bos, Kewal Asosingh, et al.
Cancers|November 24, 2019
The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple MyelomaSylvia Faict, Inge Oudaert, Ludovic D'Auria, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Plos One|November 14, 2013
Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patientsSong Xu, Gaia Cecilia Santini, Kim De Veirman, et al.
Cancers|October 14, 2022
Liquid Biopsy-Derived DNA Sources as Tools for Comprehensive Mutation Profiling in Multiple Myeloma: A Comparative StudyRobbe Heestermans, Wouter De Brouwer, Ken Maes, et al.
Cancer Research|June 18, 2009
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myelomaSarah Deleu, Miguel Lemaire, Janine Arts, et al.
Anticancer Research|December 6, 2015
Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced MelanomaLore Decoster, Isabelle Vande Broek, Bart Neyns, et al.
Acta Pharmacologica Sinica|April 9, 2013
Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivoSong Xu, Kim De Veirman, Holly Evans, et al.
Blood|June 10, 2010
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrugJinsong Hu, Damian R Handisides, Els Van Valckenborgh, et al.
Acta Clinica Belgica|September 26, 2019
Real-world data confirming the efficacy and safety of decitabine in acute myeloid leukaemia - results from a retrospective Belgian registry studyStef Meers, Benjamin Bailly, Isabelle Vande Broek, et al.
Haematologica|April 22, 2006
The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM modelEline Menu, Kewal Asosingh, Stefano Indraccolo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survivalElke De Bruyne, Tomas Jan Bos, Kewal Asosingh, et al.
Cancers|November 24, 2019
The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple MyelomaSylvia Faict, Inge Oudaert, Ludovic D'Auria, et al.
Pageof 3